These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27890173)

  • 1. Malignancy and the Risks of Biologic Therapies: Current Status.
    Seror R; Mariette X
    Rheum Dis Clin North Am; 2017 Feb; 43(1):43-64. PubMed ID: 27890173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety issues of biologics in pregnant patients with rheumatic diseases.
    Ostensen M
    Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
    Pettipher C; Benitha R
    Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biologics].
    Kalden JR
    Z Rheumatol; 2016 Aug; 75(6):604-10. PubMed ID: 27365024
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of biologics and small molecules in pregnant patients with rheumatic diseases.
    Gerosa M; Argolini LM; Artusi C; Chighizola CB
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):987-998. PubMed ID: 30227748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biologics and cardiovascular risk].
    Tarner IH; Müller-Ladner U; Hamm C
    Z Rheumatol; 2010 Oct; 69(8):702-6, 708-11. PubMed ID: 20862482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection risk and biologics: current update.
    Wallis D
    Curr Opin Rheumatol; 2014 Jul; 26(4):404-9. PubMed ID: 24827752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
    Wendling D; Di Martino V; Herbein G
    J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How dangerous are norovirus infections in patients with rheumatic diseases treated with biologics and DMARDs? Follow-up on a local outbreak and comparison with a control cohort.
    Fiehn C; Miehle N
    Ann Rheum Dis; 2014 Apr; 73(4):786-7. PubMed ID: 24276367
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment with biologics of pregnant patients with rheumatic diseases.
    Ostensen M; Förger F
    Curr Opin Rheumatol; 2011 May; 23(3):293-8. PubMed ID: 21346578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention.
    Koutsianas C; Thomas K; Vassilopoulos D
    Rheum Dis Clin North Am; 2017 Feb; 43(1):133-149. PubMed ID: 27890170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation-targeted therapies and cancer.
    Kedra J; Nocturne G; Mariette X; Seror R
    Joint Bone Spine; 2021 Jul; 88(4):105176. PubMed ID: 33771759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents.
    Ghang B; Lee D; Hwang I; Lee CK; Yoo B; Kim YG
    Clin Exp Rheumatol; 2018; 36(1):170. PubMed ID: 29352838
    [No Abstract]   [Full Text] [Related]  

  • 19. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.
    Zavada J; Dixon WG; Askling J;
    Ann Rheum Dis; 2014 Mar; 73(3):628. PubMed ID: 24058015
    [No Abstract]   [Full Text] [Related]  

  • 20. Opportunistic Infections in Biological Therapy, Risk and Prevention.
    Bryant PA; Baddley JW
    Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.